<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE Publisher PUBLIC "-//Springer-Verlag//DTD A++ V2.4//EN" "http://devel.springer.de/A++/V2.4/DTD/A++V2.4.dtd">
<Publisher>
  <PublisherInfo>
    <PublisherName>Springer-Verlag</PublisherName>
    <PublisherLocation>New York</PublisherLocation>
  </PublisherInfo>
  <Journal>
    <JournalInfo JournalProductType="ArchiveJournal" NumberingStyle="Unnumbered">
      <JournalID>12248</JournalID>
      <JournalElectronicISSN>1550-7416</JournalElectronicISSN>
      <JournalTitle>The AAPS Journal</JournalTitle>
      <JournalAbbreviatedTitle>AAPS J</JournalAbbreviatedTitle>
      <JournalSubjectGroup>
        <JournalSubject Code="F" Type="Primary">Pharmacy</JournalSubject>
        <JournalSubject Code="F00008" Priority="1" Type="Secondary">Pharmacy</JournalSubject>
        <JournalSubject Code="B21007" Priority="2" Type="Secondary">Pharmacology/Toxicology</JournalSubject>
        <JournalSubject Code="C12002" Priority="3" Type="Secondary">Biotechnology</JournalSubject>
      </JournalSubjectGroup>
    </JournalInfo>
    <Volume>
      <VolumeInfo TocLevels="0" VolumeType="Regular">
        <VolumeIDStart>7</VolumeIDStart>
        <VolumeIDEnd>7</VolumeIDEnd>
        <VolumeIssueCount>4</VolumeIssueCount>
      </VolumeInfo>
      <Issue IssueType="Regular">
        <IssueInfo TocLevels="0">
          <IssueIDStart>1</IssueIDStart>
          <IssueIDEnd>1</IssueIDEnd>
          <IssueArticleCount>25</IssueArticleCount>
          <IssueHistory>
            <CoverDate>
              <Year>2005</Year>
              <Month>3</Month>
            </CoverDate>
          </IssueHistory>
          <IssueCopyright>
            <CopyrightHolderName>American Association of Pharmaceutical Scientists</CopyrightHolderName>
            <CopyrightYear>2005</CopyrightYear>
          </IssueCopyright>
        </IssueInfo>
        <Article ID="Art2">
          <ArticleInfo ArticleType="OriginalPaper" ContainsESM="No" Language="En" NumberingStyle="Unnumbered" TocLevels="0">
            <ArticleID>71006</ArticleID>
            <ArticleDOI>10.1208/aapsj070102</ArticleDOI>
            <ArticleSequenceNumber>2</ArticleSequenceNumber>
            <ArticleTitle Language="En">A simultaneous assessment of CYP3A4 metabolism and induction in the DPX-2 cell line</ArticleTitle>
            <ArticleFirstPage>E6</ArticleFirstPage>
            <ArticleLastPage>E13</ArticleLastPage>
            <ArticleHistory>
              <RegistrationDate>
                <Year>2008</Year>
                <Month>1</Month>
                <Day>28</Day>
              </RegistrationDate>
              <Received>
                <Year>2004</Year>
                <Month>8</Month>
                <Day>12</Day>
              </Received>
              <Accepted>
                <Year>2004</Year>
                <Month>10</Month>
                <Day>20</Day>
              </Accepted>
            </ArticleHistory>
            <ArticleCopyright>
              <CopyrightHolderName>American Association of Pharmaceutical Scientists</CopyrightHolderName>
              <CopyrightYear>2005</CopyrightYear>
            </ArticleCopyright>
            <ArticleGrants Type="Regular">
              <MetadataGrant Grant="OpenAccess"/>
              <AbstractGrant Grant="OpenAccess"/>
              <BodyPDFGrant Grant="Restricted"/>
              <BodyHTMLGrant Grant="Restricted"/>
              <BibliographyGrant Grant="Restricted"/>
              <ESMGrant Grant="Restricted"/>
            </ArticleGrants>
            <ArticleContext>
              <JournalID>12248</JournalID>
              <VolumeIDStart>7</VolumeIDStart>
              <VolumeIDEnd>7</VolumeIDEnd>
              <IssueIDStart>1</IssueIDStart>
              <IssueIDEnd>1</IssueIDEnd>
            </ArticleContext>
          </ArticleInfo>
          <ArticleHeader>
            <AuthorGroup>
              <Author AffiliationIDS="Aff1" PresentAffiliationID="Aff2">
                <AuthorName DisplayOrder="Western">
                  <GivenName>Olga</GivenName>
                  <FamilyName>Trubetskoy</FamilyName>
                </AuthorName>
              </Author>
              <Author AffiliationIDS="Aff1">
                <AuthorName DisplayOrder="Western">
                  <GivenName>Bryan</GivenName>
                  <FamilyName>Marks</FamilyName>
                </AuthorName>
              </Author>
              <Author AffiliationIDS="Aff1">
                <AuthorName DisplayOrder="Western">
                  <GivenName>Thomas</GivenName>
                  <FamilyName>Zielinski</FamilyName>
                </AuthorName>
              </Author>
              <Author AffiliationIDS="Aff3">
                <AuthorName DisplayOrder="Western">
                  <GivenName>Mei-Fei</GivenName>
                  <FamilyName>Yueh</FamilyName>
                </AuthorName>
              </Author>
              <Author AffiliationIDS="Aff3" PresentAffiliationID="Aff4">
                <AuthorName DisplayOrder="Western">
                  <GivenName>Judy</GivenName>
                  <FamilyName>Raucy</FamilyName>
                </AuthorName>
                <Contact>
                  <Phone>(760) 929-9508</Phone>
                  <Fax>(760) 929-9834</Fax>
                  <Email>jraucy@puracyp.com</Email>
                </Contact>
              </Author>
              <Affiliation ID="Aff1">
                <OrgName>Invitrogen Corp</OrgName>
                <OrgAddress>
                  <Street>501 Charmany Dr</Street>
                  <Postcode>53719</Postcode>
                  <City>Madison</City>
                  <State>WI</State>
                </OrgAddress>
              </Affiliation>
              <Affiliation ID="Aff2">
                <OrgName>Quintessence Biosciences</OrgName>
                <OrgAddress>
                  <Postcode>53719</Postcode>
                  <City>Madison</City>
                  <State>WI</State>
                </OrgAddress>
              </Affiliation>
              <Affiliation ID="Aff3">
                <OrgName>Puracyp Inc</OrgName>
                <OrgAddress>
                  <Street>1989 Palomar Oaks Way, Suite B</Street>
                  <Postcode>92009</Postcode>
                  <City>Carlsbad</City>
                  <State>CA</State>
                </OrgAddress>
              </Affiliation>
              <Affiliation ID="Aff4">
                <OrgName>California Toxicology Research Institute</OrgName>
                <OrgAddress>
                  <Street>1989 Palomar Oaks Way, Suite B</Street>
                  <Postcode>92009</Postcode>
                  <City>Carlsbad</City>
                  <State>CA</State>
                </OrgAddress>
              </Affiliation>
            </AuthorGroup>
            <Abstract ID="Abs1" Language="En">
              <Heading>Abstract</Heading>
              <Para>The DPX-2 cell line, a derivative of HepG2 cells, harbors human PXR and a luciferase-linked CYP3A4 promoter. These cells were used in a panel of cell-based assays for a parallel assessment of CYP3A4 induction, metabolism, and inhibition at the cellular level. CYP3A4 induction in the DPX-2 cell line by various agents was monitored in 96-well plates by a luciferase-based transcriptional activation assay. Of the prototypical CYP3A4 inducers examined, all exhibited elevated luciferase activity in DPX-2 cells. CYP3A4 enzyme activity in noninduced and rifampicin-induced DPX-2 cells was also assessed using Vivid fluorogenic substrates. Significantly elevated CYP3A4 activity levels (2.8-fold ±0.2-fold above DMSO-treated cells) were found in DPX-2 cells after 48 hours of exposure to rifampicin, but were unde-tectable in parental HepG2 cells. Rifampicin-induced activity levels were found to be suitable for assessing the inhibitory potential of new chemical entities in downstream CYP3A4 inhibition assays. The elevated CYP3A4 activity was inhibited 85% by 10 μM ketoconazole. In addition, a cytotoxicity assay to correct for possible toxic effects of compounds at the cellular level was applied. The comparative data obtained with a combination of the above assays suggests that the application of several independent in vitro technologies used in DPX-2 cells is the best possible strategy for the assessment of the complex phenomena of CYP3A4 induction and inhibition.</Para>
            </Abstract>
            <KeywordGroup Language="En">
              <Heading>Keywords</Heading>
              <Keyword>CYP3A4</Keyword>
              <Keyword>induction</Keyword>
              <Keyword>inhibition</Keyword>
              <Keyword>DPX-2 cell line</Keyword>
              <Keyword>drug-drug interactions</Keyword>
            </KeywordGroup>
            <ArticleNote Type="Misc">
              <SimplePara>Published: March 4, 2005.</SimplePara>
            </ArticleNote>
          </ArticleHeader>
          <BodyRef FileRef="BodyRef/PDF/12248_2008_Article_71006.pdf" TargetType="OnlinePDF"/>
          <ArticleBackmatter>
            <Bibliography ID="Bib1">
              <Heading>References</Heading>
              <Citation ID="CR1">
                <CitationNumber>1.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>A</Initials>
                    <FamilyName>Bodo</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>E</Initials>
                    <FamilyName>Bakos</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>F</Initials>
                    <FamilyName>Szeri</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>A</Initials>
                    <FamilyName>Varadi</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>B</Initials>
                    <FamilyName>Sarkadi</FamilyName>
                  </BibAuthorName>
                  <Year>2003</Year>
                  <ArticleTitle Language="En">The role of multidrug transporters in drug availability, metabolism and toxicity</ArticleTitle>
                  <JournalTitle>Toxicol Lett</JournalTitle>
                  <VolumeID>140–141</VolumeID>
                  <FirstPage>133</FirstPage>
                  <LastPage>143</LastPage>
                  <Occurrence Type="PID">
                    <Handle>12676459</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/S0378-4274(02)00497-6</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD3sXisV2htrs%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Bodo A, Bakos E, Szeri F, Varadi A, Sarkadi B. The role of multidrug transporters in drug availability, metabolism and toxicity.<Emphasis Type="Italic">Toxicol Lett</Emphasis>; 2003;140–141:133–143.</BibUnstructured>
              </Citation>
              <Citation ID="CR2">
                <CitationNumber>2.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>JH</Initials>
                    <FamilyName>Ansede</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>DR</Initials>
                    <FamilyName>Thakker</FamilyName>
                  </BibAuthorName>
                  <Year>2004</Year>
                  <ArticleTitle Language="En">High-throughput screening for stability and inhibitory activity of compounds toward cytochrome P450-mediated metabolism</ArticleTitle>
                  <JournalTitle>J Pharm Sci.</JournalTitle>
                  <VolumeID>93</VolumeID>
                  <FirstPage>239</FirstPage>
                  <LastPage>255</LastPage>
                  <Occurrence Type="PID">
                    <Handle>14705182</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1002/jps.10545</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD2cXhsFagurY%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Ansede JH, Thakker DR. High-throughput screening for stability and inhibitory activity of compounds toward cytochrome P450-mediated metabolism.<Emphasis Type="Italic">J Pharm Sci.</Emphasis> 2004;93:239–255.</BibUnstructured>
              </Citation>
              <Citation ID="CR3">
                <CitationNumber>3.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>P</Initials>
                    <FamilyName>Bonnabry</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>J</Initials>
                    <FamilyName>Sievering</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>T</Initials>
                    <FamilyName>Leemann</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>P</Initials>
                    <FamilyName>Dayer</FamilyName>
                  </BibAuthorName>
                  <Year>1999</Year>
                  <ArticleTitle Language="En">Quantitative drug interactions prediction system (Q-DIPS): a computer-based prediction and management support system for drug metabolism interactions</ArticleTitle>
                  <JournalTitle>Eur J Clin Pharmacol</JournalTitle>
                  <VolumeID>55</VolumeID>
                  <FirstPage>341</FirstPage>
                  <LastPage>347</LastPage>
                  <Occurrence Type="PID">
                    <Handle>10456482</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1007/s002280050638</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaK1MXkt1Oku70%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Bonnabry P, Sievering J, Leemann T, Dayer P. Quantitative drug interactions prediction system (Q-DIPS): a computer-based prediction and management support system for drug metabolism interactions.<Emphasis Type="Italic">Eur J Clin Pharmacol</Emphasis>. 1999;55:341–347.</BibUnstructured>
              </Citation>
              <Citation ID="CR4">
                <CitationNumber>4.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>LL</Initials>
                    <FamilyName>Moltke</FamilyName>
                    <Particle>von</Particle>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>DJ</Initials>
                    <FamilyName>Greenblatt</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>J</Initials>
                    <FamilyName>Schmider</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>CE</Initials>
                    <FamilyName>Wright</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>JS</Initials>
                    <FamilyName>Harmatz</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>RI</Initials>
                    <FamilyName>Shader</FamilyName>
                  </BibAuthorName>
                  <Year>1998</Year>
                  <ArticleTitle Language="En">
                    <Emphasis Type="Italic">In vitro</Emphasis> approaches to predicting drug interactions<Emphasis Type="Italic">in vivo</Emphasis>
                  </ArticleTitle>
                  <JournalTitle>Biochem Pharmacol</JournalTitle>
                  <VolumeID>55</VolumeID>
                  <FirstPage>113</FirstPage>
                  <LastPage>122</LastPage>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/S0006-2952(97)00239-6</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>von Moltke LL, Greenblatt DJ, Schmider J, Wright CE, Harmatz JS, Shader RI.<Emphasis Type="Italic">In vitro</Emphasis> approaches to predicting drug interactions<Emphasis Type="Italic">in vivo</Emphasis>.<Emphasis Type="Italic">Biochem Pharmacol</Emphasis>. 1998;55:113–122.</BibUnstructured>
              </Citation>
              <Citation ID="CR5">
                <CitationNumber>5.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>JT</Initials>
                    <FamilyName>Moore</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>SA</Initials>
                    <FamilyName>Kliewer</FamilyName>
                  </BibAuthorName>
                  <Year>2000</Year>
                  <ArticleTitle Language="En">Use of the nuclear receptor PXR to predict drug interactions</ArticleTitle>
                  <JournalTitle>Toxicology</JournalTitle>
                  <VolumeID>153</VolumeID>
                  <FirstPage>1</FirstPage>
                  <LastPage>10</LastPage>
                  <Occurrence Type="PID">
                    <Handle>11090943</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/S0300-483X(00)00300-0</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD3cXot12ksr0%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Moore JT, Kliewer SA. Use of the nuclear receptor PXR to predict drug interactions.<Emphasis Type="Italic">Toxicology</Emphasis>. 2000;153:1–10.</BibUnstructured>
              </Citation>
              <Citation ID="CR6">
                <CitationNumber>6.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>NJ</Initials>
                    <FamilyName>Plant</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>GG</Initials>
                    <FamilyName>Gibson</FamilyName>
                  </BibAuthorName>
                  <Year>2003</Year>
                  <ArticleTitle Language="En">Evaluation of the toxicological relevance of CYP3A4 induction</ArticleTitle>
                  <JournalTitle>Curr Opin Drug Discov Devel</JournalTitle>
                  <VolumeID>6</VolumeID>
                  <FirstPage>50</FirstPage>
                  <LastPage>56</LastPage>
                  <Occurrence Type="PID">
                    <Handle>12613276</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD3sXhtFKgtrs%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Plant NJ, Gibson GG. Evaluation of the toxicological relevance of CYP3A4 induction.<Emphasis Type="Italic">Curr Opin Drug Discov Devel</Emphasis>. 2003;6:50–56.</BibUnstructured>
              </Citation>
              <Citation ID="CR7">
                <CitationNumber>7.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>PB</Initials>
                    <FamilyName>Desai</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>SC</Initials>
                    <FamilyName>Nallani</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>RS</Initials>
                    <FamilyName>Sane</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2002</Year>
                  <ArticleTitle Language="En">Induction of cytochrome P450 3A4 in primary human hepatocytes and activation of the human pregnane X receptor by tamoxifen and 4-hydroxytamoxifen</ArticleTitle>
                  <JournalTitle>Drug Metab Dispos</JournalTitle>
                  <VolumeID>30</VolumeID>
                  <FirstPage>608</FirstPage>
                  <LastPage>612</LastPage>
                  <Occurrence Type="PID">
                    <Handle>11950795</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1124/dmd.30.5.608</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD38Xjt1yqtr8%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Desai PB, Nallani SC, Sane RS, et al. Induction of cytochrome P450 3A4 in primary human hepatocytes and activation of the human pregnane X receptor by tamoxifen and 4-hydroxytamoxifen.<Emphasis Type="Italic">Drug Metab Dispos</Emphasis>. 2002;30:608–612.</BibUnstructured>
              </Citation>
              <Citation ID="CR8">
                <CitationNumber>8.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>LB</Initials>
                    <FamilyName>Moore</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>B</Initials>
                    <FamilyName>Goodwin</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>SA</Initials>
                    <FamilyName>Jones</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2000</Year>
                  <ArticleTitle Language="En">St John's wort induces hepatic drug metabolism through activation of the pregnane X receptor</ArticleTitle>
                  <JournalTitle>Proc Natl Acad Sci USA</JournalTitle>
                  <VolumeID>97</VolumeID>
                  <FirstPage>7500</FirstPage>
                  <LastPage>7502</LastPage>
                  <Occurrence Type="PID">
                    <Handle>10852961</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1073/pnas.130155097</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD3cXksVKhs7s%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Moore LB, Goodwin B, Jones SA, et al. St John's wort induces hepatic drug metabolism through activation of the pregnane X receptor.<Emphasis Type="Italic">Proc Natl Acad Sci USA</Emphasis>. 2000;97:7500–7502.</BibUnstructured>
              </Citation>
              <Citation ID="CR9">
                <CitationNumber>9.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>SA</Initials>
                    <FamilyName>Kliewer</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>B</Initials>
                    <FamilyName>Goodwin</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>TM</Initials>
                    <FamilyName>Willson</FamilyName>
                  </BibAuthorName>
                  <Year>2002</Year>
                  <ArticleTitle Language="En">The nuclear pregnane X receptor: a key regulator of xenobiotic metabolism</ArticleTitle>
                  <JournalTitle>Endocr Rev.</JournalTitle>
                  <VolumeID>23</VolumeID>
                  <FirstPage>687</FirstPage>
                  <LastPage>702</LastPage>
                  <Occurrence Type="PID">
                    <Handle>12372848</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1210/er.2001-0038</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD38XosVejtr4%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Kliewer SA, Goodwin B, Willson TM. The nuclear pregnane X receptor: a key regulator of xenobiotic metabolism.<Emphasis Type="Italic">Endocr Rev.</Emphasis> 2002;23:687–702.</BibUnstructured>
              </Citation>
              <Citation ID="CR10">
                <CitationNumber>10.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>G</Initials>
                    <FamilyName>Bertilsson</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>J</Initials>
                    <FamilyName>Heidrich</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>K</Initials>
                    <FamilyName>Svensson</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>1998</Year>
                  <ArticleTitle Language="En">Identification of a human nuclear receptor defines a new signaling pathway for<Emphasis Type="Italic">CYP3A</Emphasis> induction</ArticleTitle>
                  <JournalTitle>Proc Natl Acad Sci USA</JournalTitle>
                  <VolumeID>95</VolumeID>
                  <FirstPage>12208</FirstPage>
                  <LastPage>12213</LastPage>
                  <Occurrence Type="PID">
                    <Handle>9770465</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1073/pnas.95.21.12208</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaK1cXmsl2rs7w%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Bertilsson G, Heidrich J, Svensson K, et al. Identification of a human nuclear receptor defines a new signaling pathway for<Emphasis Type="Italic">CYP3A</Emphasis> induction.<Emphasis Type="Italic">Proc Natl Acad Sci USA</Emphasis>. 1998;95:12208–12213.</BibUnstructured>
              </Citation>
              <Citation ID="CR11">
                <CitationNumber>11.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>JM</Initials>
                    <FamilyName>Lehmann</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>DD</Initials>
                    <FamilyName>McKee</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>MA</Initials>
                    <FamilyName>Watson</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>TM</Initials>
                    <FamilyName>Willson</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>JT</Initials>
                    <FamilyName>Moore</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>SA</Initials>
                    <FamilyName>Kliewer</FamilyName>
                  </BibAuthorName>
                  <Year>1998</Year>
                  <ArticleTitle Language="En">The human orphan nuclear receptor PXR is activated by compounds that regulate<Emphasis Type="Italic">CYP3A4</Emphasis> gene expression and cause drug interactions</ArticleTitle>
                  <JournalTitle>J Clin Invest.</JournalTitle>
                  <VolumeID>102</VolumeID>
                  <FirstPage>1016</FirstPage>
                  <LastPage>1023</LastPage>
                  <Occurrence Type="PID">
                    <Handle>9727070</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1172/JCI3703</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaK1cXlvVCqtLY%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Lehmann JM, McKee DD, Watson MA, Willson TM, Moore JT, Kliewer SA. The human orphan nuclear receptor PXR is activated by compounds that regulate<Emphasis Type="Italic">CYP3A4</Emphasis> gene expression and cause drug interactions.<Emphasis Type="Italic">J Clin Invest.</Emphasis> 1998;102:1016–1023.</BibUnstructured>
              </Citation>
              <Citation ID="CR12">
                <CitationNumber>12.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>MF</Initials>
                    <FamilyName>Yueh</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>M</Initials>
                    <FamilyName>Kawahara</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>J</Initials>
                    <FamilyName>Raucy</FamilyName>
                  </BibAuthorName>
                  <Year>2004</Year>
                  <ArticleTitle Language="En">High volume bioassays to assess CYP3A4-mediated drug interactions: induction and inhibition in a single cell line</ArticleTitle>
                  <JournalTitle>Drug Metab Dispos</JournalTitle>
                  <VolumeID>33</VolumeID>
                  <FirstPage>38</FirstPage>
                  <LastPage>48</LastPage>
                  <Occurrence Type="PID">
                    <Handle>15466163</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1124/dmd.104.001594</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD2MXltlehuw%3D%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Yueh MF, Kawahara M, Raucy J. High volume bioassays to assess CYP3A4-mediated drug interactions: induction and inhibition in a single cell line.<Emphasis Type="Italic">Drug Metab Dispos</Emphasis>. 2004;33:38–48.</BibUnstructured>
              </Citation>
              <Citation ID="CR13">
                <CitationNumber>13.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>JL</Initials>
                    <FamilyName>Raucy</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>L</Initials>
                    <FamilyName>Warfe</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>M-F</Initials>
                    <FamilyName>Yueh</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>SW</Initials>
                    <FamilyName>Allen</FamilyName>
                  </BibAuthorName>
                  <Year>2002</Year>
                  <ArticleTitle Language="En">A cell-based reporter gene assay for determining induction of CYP3A4 in a high volume system</ArticleTitle>
                  <JournalTitle>J Pharmacol Exp Ther</JournalTitle>
                  <VolumeID>303</VolumeID>
                  <FirstPage>412</FirstPage>
                  <LastPage>423</LastPage>
                  <Occurrence Type="PID">
                    <Handle>12235278</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1124/jpet.102.038653</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD38XnsV2qtrc%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Raucy JL, Warfe, L, Yueh M-F, Allen SW. A cell-based reporter gene assay for determining induction of CYP3A4 in a high volume system.<Emphasis Type="Italic">J Pharmacol Exp Ther</Emphasis>. 2002;303:412–423.</BibUnstructured>
              </Citation>
              <Citation ID="CR14">
                <CitationNumber>14.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>BD</Initials>
                    <FamilyName>Marks</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>RW</Initials>
                    <FamilyName>Smith</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>HA</Initials>
                    <FamilyName>Braun</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2002</Year>
                  <ArticleTitle Language="En">A high throughput screening assay to screen for CYP2E1 metabolism and inhibition using a fluorogenic Vivid<Superscript>®</Superscript> P450 substrate</ArticleTitle>
                  <JournalTitle>Assay Drug Dev Technol</JournalTitle>
                  <VolumeID>1</VolumeID>
                  <FirstPage>73</FirstPage>
                  <LastPage>81</LastPage>
                  <Occurrence Type="PID">
                    <Handle>15090158</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1089/154065802761001329</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD38XptVejtrw%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Marks BD, Smith RW, Braun HA, et al. A high throughput screening assay to screen for CYP2E1 metabolism and inhibition using a fluorogenic Vivid<Superscript>®</Superscript> P450 substrate.<Emphasis Type="Italic">Assay Drug Dev Technol</Emphasis>. 2002;1:73–81.</BibUnstructured>
              </Citation>
              <Citation ID="CR15">
                <CitationNumber>15.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>K</Initials>
                    <FamilyName>Venkatesan</FamilyName>
                  </BibAuthorName>
                  <Year>1992</Year>
                  <ArticleTitle Language="En">Pharmacokinetic drug interactions with rifampicin</ArticleTitle>
                  <JournalTitle>Clin Pharmacokinet</JournalTitle>
                  <VolumeID>22</VolumeID>
                  <FirstPage>47</FirstPage>
                  <LastPage>65</LastPage>
                  <Occurrence Type="PID">
                    <Handle>1559307</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaK38XhsVeitLs%3D</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.2165/00003088-199222010-00005</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Venkatesan K. Pharmacokinetic drug interactions with rifampicin.<Emphasis Type="Italic">Clin Pharmacokinet</Emphasis>. 1992;22:47–65.</BibUnstructured>
              </Citation>
              <Citation ID="CR16">
                <CitationNumber>16.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>AF</Initials>
                    <FamilyName>Baker</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>RT</Initials>
                    <FamilyName>Dorr</FamilyName>
                  </BibAuthorName>
                  <Year>2001</Year>
                  <ArticleTitle Language="En">Drug interactions with the taxanes: clinical implications</ArticleTitle>
                  <JournalTitle>Cancer Treat Rev</JournalTitle>
                  <VolumeID>27</VolumeID>
                  <FirstPage>221</FirstPage>
                  <LastPage>233</LastPage>
                  <Occurrence Type="PID">
                    <Handle>11545542</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1053/ctrv.2001.0228</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD3MXnt1SktLo%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Baker AF, Dorr RT. Drug interactions with the taxanes: clinical implications.<Emphasis Type="Italic">Cancer Treat Rev</Emphasis>. 2001;27:221–233.</BibUnstructured>
              </Citation>
              <Citation ID="CR17">
                <CitationNumber>17.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>M</Initials>
                    <FamilyName>Constantinou</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>JY</Initials>
                    <FamilyName>Tsai</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>H</Initials>
                    <FamilyName>Safran</FamilyName>
                  </BibAuthorName>
                  <Year>2003</Year>
                  <ArticleTitle Language="En">Paclitaxel and concurrent radiation in upper gastrointestinal cancers</ArticleTitle>
                  <JournalTitle>Cancer Invest</JournalTitle>
                  <VolumeID>21</VolumeID>
                  <FirstPage>887</FirstPage>
                  <LastPage>896</LastPage>
                  <Occurrence Type="PID">
                    <Handle>14735693</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1081/CNV-120025092</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD3sXpvVGmurk%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Constantinou M, Tsai JY, Safran H. Paclitaxel and concurrent radiation in upper gastrointestinal cancers.<Emphasis Type="Italic">Cancer Invest</Emphasis>. 2003;21:887–896.</BibUnstructured>
              </Citation>
              <Citation ID="CR18">
                <CitationNumber>18.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>HY</Initials>
                    <FamilyName>Li</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>FR</Initials>
                    <FamilyName>Appelbaum</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>CL</Initials>
                    <FamilyName>Willman</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>RA</Initials>
                    <FamilyName>Zager</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>DE</Initials>
                    <FamilyName>Banker</FamilyName>
                  </BibAuthorName>
                  <Year>2003</Year>
                  <ArticleTitle Language="En">Cholesterol-modulating agents kill acute myeloid leukemia cells and sensitize them to therapeutics by blocking adaptive cholesterol responses</ArticleTitle>
                  <JournalTitle>Blood</JournalTitle>
                  <VolumeID>101</VolumeID>
                  <FirstPage>3628</FirstPage>
                  <LastPage>3634</LastPage>
                  <Occurrence Type="PID">
                    <Handle>12506040</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1182/blood-2002-07-2283</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD3sXjs1aqtrc%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Li HY, Appelbaum FR, Willman CL, Zager RA, Banker DE. Cholesterol-modulating agents kill acute myeloid leukemia cells and sensitize them to therapeutics by blocking adaptive cholesterol responses.<Emphasis Type="Italic">Blood</Emphasis>. 2003;101:3628–3634.</BibUnstructured>
              </Citation>
              <Citation ID="CR19">
                <CitationNumber>19.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>H</Initials>
                    <FamilyName>Shih</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>GV</Initials>
                    <FamilyName>Pickwell</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>DK</Initials>
                    <FamilyName>Guenette</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>B</Initials>
                    <FamilyName>Bilir</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>LC</Initials>
                    <FamilyName>Quattrochi</FamilyName>
                  </BibAuthorName>
                  <Year>1999</Year>
                  <ArticleTitle Language="En">Species differences in hepatocyte induction of CYP1A1 and CYP1A2 by omeprazole</ArticleTitle>
                  <JournalTitle>Hum Exp Toxicol</JournalTitle>
                  <VolumeID>18</VolumeID>
                  <FirstPage>95</FirstPage>
                  <LastPage>105</LastPage>
                  <Occurrence Type="PID">
                    <Handle>10100022</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1191/096032799678839699</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaK1MXhvVGnt70%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Shih H, Pickwell GV, Guenette DK, Bilir B, Quattrochi LC. Species differences in hepatocyte induction of CYP1A1 and CYP1A2 by omeprazole.<Emphasis Type="Italic">Hum Exp Toxicol</Emphasis>. 1999;18:95–105.</BibUnstructured>
              </Citation>
              <Citation ID="CR20">
                <CitationNumber>20.</CitationNumber>
                <BibUnstructured>Zlokarnik G, Volak LP, Andrew MM, Tran C, Cleveland T, Makings LR. Novel fluorescent probes detect different types of CYP450-drug interactions in high throughput mode. Gordon Research Conference on Drug Metabolism; July 9–14, 2000; Plymouth, NH.</BibUnstructured>
              </Citation>
              <Citation ID="CR21">
                <CitationNumber>21.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>DA</Initials>
                    <FamilyName>Flockhart</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>JR</Initials>
                    <FamilyName>Oesterheld</FamilyName>
                  </BibAuthorName>
                  <Year>2000</Year>
                  <ArticleTitle Language="En">Cytochrome P450-mediated drug interactions</ArticleTitle>
                  <JournalTitle>Child Adolesc Psychiatr Clin N Am</JournalTitle>
                  <VolumeID>9</VolumeID>
                  <FirstPage>43</FirstPage>
                  <LastPage>76</LastPage>
                  <Occurrence Type="PID">
                    <Handle>10674190</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:STN:280:DC%2BD3c7jvFWntw%3D%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Flockhart DA, Oesterheld JR. Cytochrome P450-mediated drug interactions.<Emphasis Type="Italic">Child Adolesc Psychiatr Clin N Am</Emphasis>. 2000;9:43–76.</BibUnstructured>
              </Citation>
              <Citation ID="CR22">
                <CitationNumber>22.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>KE</Initials>
                    <FamilyName>Kenworthy</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>SE</Initials>
                    <FamilyName>Clarke</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>J</Initials>
                    <FamilyName>Andrews</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>JB</Initials>
                    <FamilyName>Houston</FamilyName>
                  </BibAuthorName>
                  <Year>2001</Year>
                  <ArticleTitle Language="En">Multisite kinetic models for CYP3A4: simultaneous activation and inhibition of diazepam and testosterone metabolism</ArticleTitle>
                  <JournalTitle>Drug Metab. Dispos.</JournalTitle>
                  <VolumeID>29</VolumeID>
                  <FirstPage>1644</FirstPage>
                  <LastPage>1651</LastPage>
                  <Occurrence Type="PID">
                    <Handle>11717184</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD3MXovFKrtL4%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Kenworthy KE, Clarke SE, Andrews J, Houston JB. Multisite kinetic models for CYP3A4: simultaneous activation and inhibition of diazepam and testosterone metabolism.<Emphasis Type="Italic">Drug Metab. Dispos.</Emphasis> 2001;29:1644–1651.</BibUnstructured>
              </Citation>
              <Citation ID="CR23">
                <CitationNumber>23.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>L</Initials>
                    <FamilyName>Shen</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>JF</Initials>
                    <FamilyName>Fitzloff</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>CS</Initials>
                    <FamilyName>Cook</FamilyName>
                  </BibAuthorName>
                  <Year>2004</Year>
                  <ArticleTitle Language="En">Differential enantioselectivity and product-dependent activation and inhibition in metabolism of verapamil by human CYP3As</ArticleTitle>
                  <JournalTitle>Drug Metab Dispos</JournalTitle>
                  <VolumeID>32</VolumeID>
                  <FirstPage>186</FirstPage>
                  <LastPage>196</LastPage>
                  <Occurrence Type="PID">
                    <Handle>14744940</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1124/dmd.32.2.186</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD2cXhsVWisbg%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Shen L, Fitzloff JF, Cook CS. Differential enantioselectivity and product-dependent activation and inhibition in metabolism of verapamil by human CYP3As.<Emphasis Type="Italic">Drug Metab Dispos</Emphasis>. 2004;32:186–196. doi:10.1124/DMD.32.2.186</BibUnstructured>
              </Citation>
              <Citation ID="CR24">
                <CitationNumber>24.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>GN</Initials>
                    <FamilyName>Kumar</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>S</Initials>
                    <FamilyName>Surapaneni</FamilyName>
                  </BibAuthorName>
                  <Year>2001</Year>
                  <ArticleTitle Language="En">Role of drug metabolism in drug discovery and development</ArticleTitle>
                  <JournalTitle>Med Res Rev</JournalTitle>
                  <VolumeID>21</VolumeID>
                  <FirstPage>397</FirstPage>
                  <LastPage>411</LastPage>
                  <Occurrence Type="PID">
                    <Handle>11579440</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1002/med.1016</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD3MXmsFCmtbg%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Kumar GN, Surapaneni S. Role of drug metabolism in drug discovery and development.<Emphasis Type="Italic">Med Res Rev</Emphasis>. 2001;21:397–411.</BibUnstructured>
              </Citation>
              <Citation ID="CR25">
                <CitationNumber>25.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>RE</Initials>
                    <FamilyName>White</FamilyName>
                  </BibAuthorName>
                  <Year>2000</Year>
                  <ArticleTitle Language="En">High-throughput screening in drug metabolism and pharmacokinetic support of drug discovery</ArticleTitle>
                  <JournalTitle>Annu Rev Pharmacol Toxicol</JournalTitle>
                  <VolumeID>40</VolumeID>
                  <FirstPage>133</FirstPage>
                  <LastPage>157</LastPage>
                  <Occurrence Type="PID">
                    <Handle>10836130</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1146/annurev.pharmtox.40.1.133</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD3cXjs1yhs7w%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>White RE. High-throughput screening in drug metabolism and pharmacokinetic support of drug discovery.<Emphasis Type="Italic">Annu Rev Pharmacol Toxicol</Emphasis>. 2000;40:133–157.</BibUnstructured>
              </Citation>
              <Citation ID="CR26">
                <CitationNumber>26.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>EL</Initials>
                    <FamilyName>Michalets</FamilyName>
                  </BibAuthorName>
                  <Year>1998</Year>
                  <ArticleTitle Language="En">Update: clinically significant cytochrome P450 drug interactions</ArticleTitle>
                  <JournalTitle>Pharmacotherapy</JournalTitle>
                  <VolumeID>18</VolumeID>
                  <FirstPage>84</FirstPage>
                  <LastPage>112</LastPage>
                  <Occurrence Type="PID">
                    <Handle>9469685</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaK1cXpt1ylug%3D%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Michalets EL. Update: clinically significant cytochrome P450 drug interactions.<Emphasis Type="Italic">Pharmacotherapy</Emphasis>. 1998;18:84–112.</BibUnstructured>
              </Citation>
              <Citation ID="CR27">
                <CitationNumber>27.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>GK</Initials>
                    <FamilyName>Dresser</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>JD</Initials>
                    <FamilyName>Spence</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>DG</Initials>
                    <FamilyName>Bailey</FamilyName>
                  </BibAuthorName>
                  <Year>2000</Year>
                  <ArticleTitle Language="En">Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition</ArticleTitle>
                  <JournalTitle>Clin Pharmacokinet</JournalTitle>
                  <VolumeID>38</VolumeID>
                  <FirstPage>41</FirstPage>
                  <LastPage>57</LastPage>
                  <Occurrence Type="PID">
                    <Handle>10668858</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.2165/00003088-200038010-00003</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD3cXhtV2kurw%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Dresser GK, Spence JD, Bailey DG. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.<Emphasis Type="Italic">Clin Pharmacokinet</Emphasis>. 2000;38:41–57.</BibUnstructured>
              </Citation>
              <Citation ID="CR28">
                <CitationNumber>28.</CitationNumber>
                <BibChapter>
                  <BibAuthorName>
                    <Initials>A</Initials>
                    <FamilyName>Parkinson</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>A</Initials>
                    <FamilyName>Madan</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>J</Initials>
                    <FamilyName>Forster</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>1997</Year>
                  <ChapterTitle Language="En">Enzyme induction: assessing the potential for drug interactions</ChapterTitle>
                  <BibEditorName>
                    <Initials>W</Initials>
                    <FamilyName>Hori</FamilyName>
                  </BibEditorName>
                  <Eds/>
                  <BookTitle>Drug-Drug Interactions: Analyzing in vitro-in vivo correlations</BookTitle>
                  <PublisherName>International Business Communications, Inc</PublisherName>
                  <PublisherLocation>Westborough, Massachusetts</PublisherLocation>
                  <FirstPage>1</FirstPage>
                  <LastPage>33</LastPage>
                </BibChapter>
                <BibUnstructured>Parkinson A, Madan A, Forster J, et al. Enzyme induction: assessing the potential for drug interactions. In: Hori W, ed.<Emphasis Type="Italic">Drug-Drug Interactions: Analyzing in vitro-in vivo correlations</Emphasis>. Westborough, Massachusetts: International Business Communications, Inc; 1997, 1–33.</BibUnstructured>
              </Citation>
              <Citation ID="CR29">
                <CitationNumber>29.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>GW</Initials>
                    <FamilyName>Caldwell</FamilyName>
                  </BibAuthorName>
                  <Year>2000</Year>
                  <ArticleTitle Language="En">Compound optimization in early- and late-phase drug discovery: acceptable pharmacokinetics properties utilizing combined physiochemical, in vitro and in vivo screens</ArticleTitle>
                  <JournalTitle>Curr Opin Drug Discov Devel</JournalTitle>
                  <VolumeID>3</VolumeID>
                  <FirstPage>30</FirstPage>
                  <LastPage>41</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD3cXht1ymu7w%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Caldwell GW. Compound optimization in early- and late-phase drug discovery: acceptable pharmacokinetics properties utilizing combined physiochemical, in vitro and in vivo screens.<Emphasis Type="Italic">Curr Opin Drug Discov Devel</Emphasis>. 2000;3:30–41.</BibUnstructured>
              </Citation>
              <Citation ID="CR30">
                <CitationNumber>30.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>U</Initials>
                    <FamilyName>Fuhr</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>M</Initials>
                    <FamilyName>Weiss</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>HK</Initials>
                    <FamilyName>Kroemer</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>1996</Year>
                  <ArticleTitle Language="En">Systematic screening for pharmacokinetic interactions during drug development</ArticleTitle>
                  <JournalTitle>J Clin Pharmacol Therap</JournalTitle>
                  <VolumeID>34</VolumeID>
                  <FirstPage>139</FirstPage>
                  <LastPage>151</LastPage>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaK28XivFams7o%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Fuhr U, Weiss M, Kroemer HK, et al. Systematic screening for pharmacokinetic interactions during drug development.<Emphasis Type="Italic">J Clin Pharmacol Therap</Emphasis>. 1996;34:139–151.</BibUnstructured>
              </Citation>
              <Citation ID="CR31">
                <CitationNumber>31.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>AD</Initials>
                    <FamilyName>Rodrigues</FamilyName>
                  </BibAuthorName>
                  <Year>1994</Year>
                  <ArticleTitle Language="En">Use of<Emphasis Type="Italic">in vitro</Emphasis> human metabolism studies in drug development: An industrial perspective</ArticleTitle>
                  <JournalTitle>Biochem Pharmacol</JournalTitle>
                  <VolumeID>48</VolumeID>
                  <FirstPage>2147</FirstPage>
                  <LastPage>2156</LastPage>
                  <Occurrence Type="PID">
                    <Handle>7811296</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/0006-2952(94)00312-2</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DyaK2MXivFGlsrY%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Rodrigues AD. Use of<Emphasis Type="Italic">in vitro</Emphasis> human metabolism studies in drug development: An industrial perspective.<Emphasis Type="Italic">Biochem Pharmacol</Emphasis>. 1994;48:2147–2156.</BibUnstructured>
              </Citation>
              <Citation ID="CR32">
                <CitationNumber>32.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>JL</Initials>
                    <FamilyName>Raucy</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>L</Initials>
                    <FamilyName>Mueller</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>K</Initials>
                    <FamilyName>Duan</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>SW</Initials>
                    <FamilyName>Allen</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>S</Initials>
                    <FamilyName>Strom</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>JM</Initials>
                    <FamilyName>Lasker</FamilyName>
                  </BibAuthorName>
                  <Year>2002</Year>
                  <ArticleTitle Language="En">Expression and induction of CYP2C P450 enzymes in primary cultures of human, hepatocytes</ArticleTitle>
                  <JournalTitle>J Pharmacol, Exp Ther</JournalTitle>
                  <VolumeID>302</VolumeID>
                  <FirstPage>475</FirstPage>
                  <LastPage>482</LastPage>
                  <Occurrence Type="DOI">
                    <Handle>10.1124/jpet.102.033837</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD38Xls1Ogsb8%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Raucy JL, Mueller L, Duan K, Allen SW, Strom S, Lasker JM. Expression and induction of CYP2C P450 enzymes in primary cultures of human, hepatocytes.<Emphasis Type="Italic">J Pharmacol, Exp Ther</Emphasis>. 2002;302:475–482.</BibUnstructured>
              </Citation>
              <Citation ID="CR33">
                <CitationNumber>33.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>JL</Initials>
                    <FamilyName>Raucy</FamilyName>
                  </BibAuthorName>
                  <Year>2003</Year>
                  <ArticleTitle Language="En">Regulation of CYP3A4 expression in human hepatocytes by pharmaceuticals and natural products</ArticleTitle>
                  <JournalTitle>Drug Metab Dispos</JournalTitle>
                  <VolumeID>31</VolumeID>
                  <FirstPage>533</FirstPage>
                  <LastPage>539</LastPage>
                  <Occurrence Type="PID">
                    <Handle>12695340</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1124/dmd.31.5.533</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD3sXjt1Ggt74%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Raucy JL. Regulation of CYP3A4 expression in human hepatocytes by pharmaceuticals and natural products.<Emphasis Type="Italic">Drug Metab Dispos</Emphasis>. 2003;31:533–539.</BibUnstructured>
              </Citation>
              <Citation ID="CR34">
                <CitationNumber>34.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>G</Initials>
                    <FamilyName>Luo</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>M</Initials>
                    <FamilyName>Cunningham</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>S</Initials>
                    <FamilyName>Kim</FamilyName>
                  </BibAuthorName>
                  <Etal/>
                  <Year>2002</Year>
                  <ArticleTitle Language="En">CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes</ArticleTitle>
                  <JournalTitle>Drug Metab. Disp.</JournalTitle>
                  <VolumeID>30</VolumeID>
                  <FirstPage>795</FirstPage>
                  <LastPage>804</LastPage>
                  <Occurrence Type="DOI">
                    <Handle>10.1124/dmd.30.7.795</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD38XltVGru78%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Luo G, Cunningham M, Kim S, et al. CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes.<Emphasis Type="Italic">Drug Metab. Disp.</Emphasis> 2002;30:795–804.</BibUnstructured>
              </Citation>
              <Citation ID="CR35">
                <CitationNumber>35.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>NJ</Initials>
                    <FamilyName>Plant</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>MS</Initials>
                    <FamilyName>Ogg</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>M</Initials>
                    <FamilyName>Crowder</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>GG</Initials>
                    <FamilyName>Gibson</FamilyName>
                  </BibAuthorName>
                  <Year>2000</Year>
                  <ArticleTitle Language="En">Control and statistical analysis of<Emphasis Type="Italic">in vitro</Emphasis> reporter gene assays</ArticleTitle>
                  <JournalTitle>Anal Biochem</JournalTitle>
                  <VolumeID>278</VolumeID>
                  <FirstPage>170</FirstPage>
                  <LastPage>174</LastPage>
                  <Occurrence Type="PID">
                    <Handle>10660459</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1006/abio.1999.4460</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD3cXoslKjtA%3D%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Plant NJ, Ogg MS, Crowder M, Gibson GG. Control and statistical analysis of<Emphasis Type="Italic">in vitro</Emphasis> reporter gene assays.<Emphasis Type="Italic">Anal Biochem</Emphasis>. 2000;278:170–174.</BibUnstructured>
              </Citation>
              <Citation ID="CR36">
                <CitationNumber>36.</CitationNumber>
                <BibArticle>
                  <BibAuthorName>
                    <Initials>BC</Initials>
                    <FamilyName>Spink</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>MM</Initials>
                    <FamilyName>Hussain</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>BH</Initials>
                    <FamilyName>Katz</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>L</Initials>
                    <FamilyName>Eisele</FamilyName>
                  </BibAuthorName>
                  <BibAuthorName>
                    <Initials>DC</Initials>
                    <FamilyName>Spink</FamilyName>
                  </BibAuthorName>
                  <Year>2003</Year>
                  <ArticleTitle Language="En">Transient induction of cytochromes P450 1A1 and 1B1 in MCF-7 human breast cancer cells indirubin</ArticleTitle>
                  <JournalTitle>Biochem Pharmacol</JournalTitle>
                  <VolumeID>66</VolumeID>
                  <FirstPage>2313</FirstPage>
                  <LastPage>2321</LastPage>
                  <Occurrence Type="PID">
                    <Handle>14637189</Handle>
                  </Occurrence>
                  <Occurrence Type="DOI">
                    <Handle>10.1016/j.bcp.2003.08.019</Handle>
                  </Occurrence>
                  <Occurrence Type="COI">
                    <Handle>1:CAS:528:DC%2BD3sXptVWmsLo%3D</Handle>
                  </Occurrence>
                </BibArticle>
                <BibUnstructured>Spink BC, Hussain MM, Katz BH, Eisele L, Spink DC. Transient induction of cytochromes P450 1A1 and 1B1 in MCF-7 human breast cancer cells indirubin.<Emphasis Type="Italic">Biochem Pharmacol</Emphasis>. 2003;66:2313–2321.</BibUnstructured>
              </Citation>
            </Bibliography>
          </ArticleBackmatter>
        </Article>
      </Issue>
    </Volume>
  </Journal>
</Publisher>
